New pathogenic paradigms in inflammatory bowel disease

Antonio Di Sabatino, Paolo Biancheri, Laura Rovedatti, Thomas T. MacDonald, Gino R. Corazza

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer "static" but "dynamic" vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.

Original languageEnglish
Pages (from-to)368-371
Number of pages4
JournalInflammatory Bowel Diseases
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Inflammatory Bowel Diseases
Th17 Cells
Th1 Cells
Adaptive Immunity
Innate Immunity
Inflammation
Therapeutics

Keywords

  • Crohn's disease
  • cytokines
  • mucosal immunology
  • T cell
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

New pathogenic paradigms in inflammatory bowel disease. / Di Sabatino, Antonio; Biancheri, Paolo; Rovedatti, Laura; MacDonald, Thomas T.; Corazza, Gino R.

In: Inflammatory Bowel Diseases, Vol. 18, No. 2, 02.2012, p. 368-371.

Research output: Contribution to journalArticle

@article{187d483260534244bf353166f03d6ad8,
title = "New pathogenic paradigms in inflammatory bowel disease",
abstract = "Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer {"}static{"} but {"}dynamic{"} vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.",
keywords = "Crohn's disease, cytokines, mucosal immunology, T cell, ulcerative colitis",
author = "{Di Sabatino}, Antonio and Paolo Biancheri and Laura Rovedatti and MacDonald, {Thomas T.} and Corazza, {Gino R.}",
year = "2012",
month = "2",
doi = "10.1002/ibd.21735",
language = "English",
volume = "18",
pages = "368--371",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - New pathogenic paradigms in inflammatory bowel disease

AU - Di Sabatino, Antonio

AU - Biancheri, Paolo

AU - Rovedatti, Laura

AU - MacDonald, Thomas T.

AU - Corazza, Gino R.

PY - 2012/2

Y1 - 2012/2

N2 - Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer "static" but "dynamic" vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.

AB - Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer "static" but "dynamic" vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.

KW - Crohn's disease

KW - cytokines

KW - mucosal immunology

KW - T cell

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84855672962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855672962&partnerID=8YFLogxK

U2 - 10.1002/ibd.21735

DO - 10.1002/ibd.21735

M3 - Article

C2 - 21538717

AN - SCOPUS:84855672962

VL - 18

SP - 368

EP - 371

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 2

ER -